Replimune Group Inc (REPL)
NASDAQ:REPL
REPL Stock Chart & Stats
$1.70
$0.17(1.56%)
At close: 4:00 PM EST
$1.70
$0.17(1.56%)
Day’s Range― - ―
52-Week Range$1.50 - $13.24
Previous CloseN/A
Volume95.41K
Average Volume (3M)2.32M
Market Cap
$393.05M
Enterprise Value$96.28M
Total Cash (Recent Filing)$269.14M
Total Debt (Recent Filing)$78.86M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
May 14, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding82,572,620
10 Day Avg. Volume3,747,062
30 Day Avg. Volume2,318,085
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.89
Price to Sales (P/S)0.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-113.54
Enterprise Value/Ebitda-0.31
Forecast
1Y Price Target
$2.25Price Target Upside32.35% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering7
EPS Forecast (FY)-2.04
Revenue Forecast (FY)$43.62M
Bulls Say, Bears Say
Bulls Say
Cash Runway And FinancingAmended loan facility and existing cash balance provide sufficient resources to fund initial commercial activities if RP1 is approved, reducing near-term funding pressure.
Commercial PotentialRP1 is viewed as a genuine therapeutic addressing a high unmet need in advanced melanoma, supporting meaningful commercial upside if approved.
Market Perception And TurnaroundRegulatory approval of RP1 would represent a significant turnaround event that could restore investor confidence and lead to a stock re-rating.
Bears Say
Analyst Downgrade And Restructuring RiskAnalyst downgrade to Neutral and expectations of company restructuring indicate a higher likelihood of cost cutting and strategic shifts to conserve cash while pursuing a more rigorous pivotal trial.
Regulatory SetbacksFDA complete response letters and a unanimously critical review from the agency highlight major regulatory misalignment that could delay approval or require substantial additional work.
Trial Design And Data InterpretabilityAgency concerns about reliance on single-arm trials, absence of a control arm, reinjection and surgical procedures, and wide patient heterogeneity make efficacy assessment unclear and weaken the approval case.
Replimune Group News
REPL FAQ
What was Replimune Group Inc’s price range in the past 12 months?
Replimune Group Inc lowest stock price was $1.50 and its highest was $13.24 in the past 12 months.
What is Replimune Group Inc’s market cap?
Replimune Group Inc’s market cap is $393.05M.
When is Replimune Group Inc’s upcoming earnings report date?
Replimune Group Inc’s upcoming earnings report date is May 14, 2026 which is in 29 days.
How were Replimune Group Inc’s earnings last quarter?
Replimune Group Inc released its earnings results on Feb 03, 2026. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.763 by -$0.007.
Is Replimune Group Inc overvalued?
According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued.
Does Replimune Group Inc pay dividends?
Replimune Group Inc does not currently pay dividends.
What is Replimune Group Inc’s EPS estimate?
Replimune Group Inc’s EPS estimate is -0.65.
How many shares outstanding does Replimune Group Inc have?
Replimune Group Inc has 82,572,620 shares outstanding.
What happened to Replimune Group Inc’s price movement after its last earnings report?
Replimune Group Inc reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.763. Following the earnings report the stock price went up 5.806%.
Which hedge fund is a major shareholder of Replimune Group Inc?
Currently, no hedge funds are holding shares in REPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Replimune Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$2.25 (32.35% Upside)
$2.25 (32.35% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 315.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.21%
12-Months-Change
Fundamentals
Return on Equity
-102.69%
Trailing 12-Months
Asset Growth
-44.74%
Trailing 12-Months
Company Description
Replimune Group Inc
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$2.25
▲(32.35% Upside)
Technical Analysis
Anavex Life Sciences
―
Arcus Biosciences
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
Currently, No data available
---